Status:
COMPLETED
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Lead Sponsor:
EuBiologics Co.,Ltd
Conditions:
Glabellar Frown Lines
Eligibility:
All Genders
19-65 years
Phase:
PHASE3
Brief Summary
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.
Eligibility Criteria
Inclusion
- Healthy male and female aged 19 to 65 years old
- Participants with Facial Wrinkle Scale (FWS) score of \> 2 at maximum frown at screening
- Participants willing to follow the study procedures and schedules
- Participants willing to give written informed consent to participate in the trial
Exclusion
- Participants with severe glabellar lines that cannot be improved physical method
- Pregnant, lactating women or women of childbearing age not using a reliable method of contraception
- Participants with known hypersensitivity to any component of the study drug
- Participant who has skin disorder including infection and scar on injection site
Key Trial Info
Start Date :
June 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT04830345
Start Date
June 29 2020
End Date
October 1 2021
Last Update
April 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nowon Eulji University Hospital
Seoul, South Korea